CNS Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	2	7	3	20	30	65	-
Market Cap Growth	-	108.14%	-83.67%	-33.84%	-54.38%	-	-
Enterprise Value	2	6	-6	15	16	58	-0
PE Ratio	-0.35	-0.35	-0.21	-1.35	-3.13	-16.76	-
PB Ratio	-1.50	-1.50	0.39	3.18	2.13	8.55	-
P/FCF Ratio	-0.47	-0.47	-0.30	-1.45	-4.04	-18.18	-
P/OCF Ratio	-0.47	-0.47	-0.30	-1.45	-4.05	-18.29	-
EV/EBITDA Ratio	-0.34	-0.34	0.42	-1.04	-1.70	-15.00	0.03
EV/EBIT Ratio	-0.34	-0.34	0.42	-1.04	-1.70	-14.99	0.03
EV/FCF Ratio	-0.45	-0.45	0.61	-1.11	-2.19	-16.16	0.33
Debt / Equity Ratio	-0.07	-0.07	0.05	0.06	0.03	-	-0.58
Debt / EBITDA Ratio	-0.02	-0.02	-0.03	-0.03	-0.05	-	-0.04
Debt / FCF Ratio	-0.02	-0.02	-0.04	-0.03	-0.06	-	-0.44
Quick Ratio	0.09	0.09	2.04	1.93	7.37	23.28	0.45
Current Ratio	0.26	0.26	2.55	2.88	8.13	25.38	0.48
Interest Coverage	-1364.54	-1364.54	-2172.64	-1560.14	-2896.63	-147.26	-257.32
Return on Equity (ROE)	33276.20%	33276.20%	-142.60%	-149.00%	-145.40%	-110.00%	2432.20%
Return on Assets (ROA)	-421.40%	-421.40%	-119.80%	-121.70%	-130.30%	-90.20%	-1748.50%
Return on Capital (ROIC)	456.64%	456.64%	-178.71%	-221.13%	-65.72%	-50.43%	379.46%
Earnings Yield	-824.46%	-282.81%	-476.93%	-73.91%	-31.91%	-5.97%	-
FCF Yield	-618.58%	-212.19%	-329.81%	-69.06%	-24.75%	-5.50%	-
Buyback Yield / Dilution	-176.66%	-176.66%	-55.02%	-58.58%	-21.77%	-29.85%	-
Total Shareholder Return	-176.66%	-176.66%	-55.02%	-58.58%	-21.77%	-29.85%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).